Nonalcoholic Fatty Liver Disease Activity Score

1. Weight reduction of at least 7% decreases Nonalcoholic Fatty Liver Disease Activity Score in humans (non-lean NASH only).

   “However, significant improvement in NAS was noted with ≥ 7% weight reduction in non-lean group only.”

   Human trialnon-lean NASH onlyliver7% or more weight reduction1 yearn = 16

   Effect of Weight Reduction on Histological Activity and Fibrosis of Lean Nonalcoholic Steatohepatitis Patient

   Journal of translational internal medicine·Oct 12, 2019

More on Weight reduction of at least 7%

1. Weight reduction of at least 5% decreases Nonalcoholic Fatty Liver Disease Activity Score in humans (weight reduction of 5% or more in lean and non-lean NASH).

   “In both groups, weight reduction of ≥ 5% was associated with significant reduction in NAS only.”

   Human trialweight reduction of 5% or more in lean and non-lean NASHliver5% or more weight reduction1 year

   Effect of Weight Reduction on Histological Activity and Fibrosis of Lean Nonalcoholic Steatohepatitis Patient

   Journal of translational internal medicine·Oct 12, 2019

More on Weight reduction of at least 5%

1. Weight reduction decreases Nonalcoholic Fatty Liver Disease Activity Score in humans (any amount of weight reduction in lean and non-lean NASH).

   “In both lean and non-lean groups, weight reduction of any amount was associated with significant reduction of steatosis, ballooning and NAS, except lobular inflammation and fibrosis.”

   Human trialany amount of weight reduction in lean and non-lean NASHliver1 year

   Effect of Weight Reduction on Histological Activity and Fibrosis of Lean Nonalcoholic Steatohepatitis Patient

   Journal of translational internal medicine·Oct 12, 2019

More on Weight reduction

1. β3-adrenergic receptor agonist showed no clear effect on Nonalcoholic Fatty Liver Disease Activity Score in mice (high-fat diet-fed foz/foz mice with established NASH).

   “but had no impact on liver inflammation or on nonalcoholic fatty liver disease activity score (NAS).”

   Animalshigh-fat diet-fed foz/foz mice with established NASHliver

   Activation of brown adipose tissue enhances the efficacy of caloric restriction for treatment of nonalcoholic steatohepatitis

   Laboratory investigation; a journal of technical methods and pathology·Sep 26, 2018

More on β3-adrenergic receptor agonist